🇺🇸 FDA
Pipeline program

TVB-2640

22-08025117

Phase 1 small_molecule active

Quick answer

TVB-2640 for Prostatic Neoplasms, Castration-Resistant is a Phase 1 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Sagimet Biosciences
Indication
Prostatic Neoplasms, Castration-Resistant
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials